The tamoxifen paradox—influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer

Summary Our data demonstrate that tamoxifen does not reduce fracture risk. Close surveillance is necessary to prevent bone loss in premenopausal women with breast cancer upon treatment initiation. Introduction Endocrine treatment of breast cancer may interfere with bone turnover and influence fractu...

Full description

Saved in:
Bibliographic Details
Published in:Osteoporosis international 2018-11, Vol.29 (11), p.2557-2564
Main Authors: Kyvernitakis, I., Kostev, K., Hadji, P.
Format: Article
Language:English
Subjects:
Adjuvants
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Bone cancer
Bone loss
Bone turnover
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - epidemiology
Chemotherapy, Adjuvant - adverse effects
Databases, Factual
Endocrinology
Female
Fractures
Germany - epidemiology
Health risk assessment
Humans
Incidence
Medicine
Medicine & Public Health
Middle Aged
Original Article
Orthopedics
Osteoporosis
Osteoporotic Fractures - chemically induced
Osteoporotic Fractures - epidemiology
Patients
Post-menopause
Postmenopause
Premenopause
Retrospective Studies
Rheumatology
Risk Assessment - methods
Tamoxifen
Tamoxifen - adverse effects
Tamoxifen - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Our data demonstrate that tamoxifen does not reduce fracture risk. Close surveillance is necessary to prevent bone loss in premenopausal women with breast cancer upon treatment initiation. Introduction Endocrine treatment of breast cancer may interfere with bone turnover and influence fracture risk. Methods Out of a cohort of almost 5 million patients in total, we identified 5520 women between 18 and 90 years of age with breast cancer receiving tamoxifen, matched them with 5520 healthy controls using the Disease Analyzer Database, and investigated the fracture risk. Results We found a cumulative incidence of fractures of 6.3% in patients aged between 18 and 50 years ( n  = 3634) treated with tamoxifen versus a cumulative incidence of 3.6% in the control group ( p  
ISSN:0937-941X
1433-2965
DOI:10.1007/s00198-018-4642-2